VisszavonvaFázis nélkül
Safety and Efficacy of IrisFIT™ Patent Foramen Ovale Occluders
A legfontosabb adatok
- Ki végzi
- Lifetech Scientific (Shenzhen) Co., Ltd.
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Visszavonva
- Kezdés
- 2022. ápr. 12.
- Várható befejezés
- 2028. márc. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Iris FIT™ PFO closure system
- A regiszteradat frissítve
- 2023. március 14.
- Miért állt le
- Company policy
Ki vehet részt
- Életkor
- 18 év – 60 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Patients aged 18-60 years
- Be able to understand the purpose of the experiment, voluntarily participate in the experiment and sign the informed consent
- Patent foramen ovale was confirmed by chest ultrasound (TTE) or esophageal ultrasound (TEE)
- The presence of a large right-to-left shunt was confirmed by right aspiration angiography (cTTE or cTCD)
- It meets the clinical status of patent foramen ovale plugging indication, and at least one of the following conditions exists:; Cryptogenic stroke complicated with patent foramen ovale, combined with one or more clinical risk factors; Cryptogenic stroke complicated with patent foramen ovale, combined with one or more anatomical risk factors of patent foramen ovale; Cryptogenic stroke complicated with patent foramen ovale, with clear deep vein thrombosis or pulmonary embolism, and not suitable for anticoagulant therapy; Cryptogenic stroke complicated with patent foramen ovale, but still recurred with antiplatelet or anticoagulant therapy
Ki nem vehet részt
- Mitral/aortic disease: including mitral stenosis or severe mitral regurgitation of any cause, severe aortic stenosis or severe aortic regurgitation, mitral or aortic valve vegetations or prior valve replacement surgery
- Participate in clinical trials of other drugs or medical devices within three months
- intracardiac thrombosis or tumor, intracardiac neoplasm
- acute myocardial infarction or unstable angina within 6 months
- Left ventricular aneurysm formation or left ventricular wall movement disorder
- Patients with active endocarditis or other untreated infections or other hemorrhagic diseases
- Pulmonary hypertension or patent foramen ovale was a special channel
- Uncontrolled hypertension (> 180/100 mmHg)
- Contraindication of antiplatelet or anticoagulant therapy, such as severe bleeding within 3 months, obvious retinopathy, history of other intracranial bleeding, and obvious intracranial diseases
- Coronary heart disease, hypertension, diabetes and other vascular diseases that are poorly controlled by drugs or other means
- Thrombosis exists at the location or route of implantation
- Malignant neoplasms or other diseases with a life expectancy of less than 2 years
- Dilated cardiomyopathy, LVEF < 35%, or other severe heart failure
- liver and kidney function impairment (ALT or AST > 3 times the upper limit of normal value, serum creatinine (Cr) > 2 times the upper limit of normal value)
- Carotid atherosclerotic stenosis was determined by the investigator based on CT or vascular ultrasound (> 50%)
- Large cerebral infarction occurred within 4 weeks (MR/CT or DWI image ASPECTS score <6 points or infarction volume ≥70 ml or infarction area > 1/3 middle cerebral artery blood supply area)
- Patients with right-to-left shunt due to other causes, including atrial septal defect or perforated diaphragm
- Atrial fibrillation/atrial flutter (chronic or intermittent)
- pregnant or planning to become pregnant during the trial
- The investigator determined that the patient was not suitable for implantation of PFO occluder (for example, the diameter of the base of the atrial septal tumor ≥25mm and the size of the foramen ovale ≥5mm) or the patient has contraindications for implantation of PFO occluder
- Patients who could not be followed up during the trial
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the performance of patent foramen ovale (PFO) device developed by Lifetech Technology (Shenzhen) Co., LTD
A vizsgálat csoportja
- Intervention armA vizsgált kezelés
Patients with cryptogenic stroke complicated with patent foramen ovale,and passed the screening and signed the informed consent form
Kezelés: Iris FIT™ PFO closure system
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Multi-Center, Single-Group Goal Value Clinical Trial to Revaluate the Safety and Efficacy of Patent Foramen Ovale Occluders
- A regiszteradat frissítve
- 2023. március 14.